Evidence map›Paper›PMID 28647518›Full record

ArticleJournal of proteomics2017

Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.

P Patrizia Mangione, Giuseppe Mazza, Janet A Gilbertson, Nigel B Rendell, Diana Canetti, Sofia Giorgetti, Luca Frenguelli, Marco Curti, Tamer Rezk, Sara Raimondi and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of proteomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

P Patrizia MangioneWolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London, UK; Department of Molecular Medicine, Institute of Biochemistry, University of Pavia, Pavia, Italy.
Giuseppe MazzaInstitute for Liver and Digestive Health, University College London, London, UK.
Janet A GilbertsonNational Amyloidosis Centre, University College London and Royal Free Hospital, London, UK.
Nigel B RendellWolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London, UK.
Diana CanettiWolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London, UK; Department of Molecular Medicine, Institute of Biochemistry, University of Pavia, Pavia, Italy; CEINGE and Department of Chemical Sciences, University of Naples, Naples, Italy.
Sofia GiorgettiDepartment of Molecular Medicine, Institute of Biochemistry, University of Pavia, Pavia, Italy.
Luca FrenguelliInstitute for Liver and Digestive Health, University College London, London, UK.
Marco CurtiInstitute for Liver and Digestive Health, University College London, London, UK.
Tamer RezkNational Amyloidosis Centre, University College London and Royal Free Hospital, London, UK.
Sara RaimondiDepartment of Molecular Medicine, Institute of Biochemistry, University of Pavia, Pavia, Italy.
Mark B PepysWolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London, UK; National Amyloidosis Centre, University College London and Royal Free Hospital, London, UK.
Philip N HawkinsNational Amyloidosis Centre, University College London and Royal Free Hospital, London, UK.
Julian D GillmoreNational Amyloidosis Centre, University College London and Royal Free Hospital, London, UK.
Graham W TaylorWolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London, UK.
Massimo PinzaniInstitute for Liver and Digestive Health, University College London, London, UK. Electronic address: m.pinzani@ucl.ac.uk.
Vittorio BellottiWolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London, UK; Department of Molecular Medicine, Institute of Biochemistry, University of Pavia, Pavia, Italy. Electronic address: v.bellotti@ucl.ac.uk.
University College London · GBThe Royal Free Hospital · GBUniversity of Pavia · ITUniversity of Naples Federico II · IT

Funding

Medical Research Council G7900510Medical Research Council MR/K000187/1
6 · The paper itself

Abstract

Diagnosis and treatment of systemic amyloidosis depend on accurate identification of the specific amyloid fibril protein forming the tissue deposits. Confirmation of monoclonal immunoglobulin light chain amyloidosis (AL), requiring cytotoxic chemotherapy, and avoidance of such treatment in non-AL amyloidosis, are particularly important. Proteomic analysis characterises amyloid proteins directly. It complements immunohistochemical staining of amyloid to identify fibril proteins and gene sequencing to identify mutations in the fibril precursors. However, proteomics sometimes detects more than one potentially amyloidogenic protein, especially immunoglobulins and transthyretin which are abundant plasma proteins. Ambiguous results are most challenging in the elderly as both AL and transthyretin (ATTR) amyloidosis are usually present in this group. We have lately described a procedure for tissue decellularisation which retains the structure, integrity and composition of amyloid but removes proteins that are not integrated within the deposits. Here we show that use of this procedure before proteomic analysis eliminates ambiguity and improves diagnostic accuracy. SIGNIFICANCE: Unequivocal identification of the protein causing amyloidosis disease is crucial for correct diagnosis and treatment. As a proof of principle, we selected a number of cardiac and fat tissue biopsies from patients with various types of amyloidosis and show that a classical procedure of decellularisation enhances the specificity of the identification of the culprit protein reducing ambiguity and the risk of misdiagnosis.

Indexed as

Adipose TissueAmyloidAmyloidosisBiopsyCell-Free SystemHumansImmunoglobulin Light ChainsMyocardiumPrealbuminProteomicsSensitivity and SpecificityAmyloidImmunoglobulin Light ChainsPrealbuminAmyloidosisAmyloid typingDecellularisationProteomics

Identifiers

PMID28647518
PMCPMC5571436
OpenAlexW2655169797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.